

# Sophie Lestavel

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1360057/sophie-lestavel-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45  
papers

3,171  
citations

26  
h-index

46  
g-index

46  
ext. papers

3,485  
ext. citations

7.7  
avg, IF

4.09  
L-index

#	Paper	IF	Citations
45	Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System.. <i>Frontiers in Molecular Neuroscience</i> , <b>2021</b> , 14, 808603	6.1	0
44	Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2021</b> , 320, E772-E783	6	3
43	Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 1593-1610	8.3	2
42	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 123, 154844	12.7	4
41	The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. <i>Scientific Reports</i> , <b>2020</b> , 10, 174	4.9	23
40	Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. <i>Gut</i> , <b>2018</b> , 67, 271-283	19.2	100
39	Food-Derived Hemorphins Cross Intestinal and Blood-Brain Barriers. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 159	5.7	9
38	Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs. <i>International Journal of Obesity</i> , <b>2017</b> , 41, 664-668	5.5	18
37	Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 4185-4211	8.3	35
36	Ffar2 expression regulates leukaemic cell growth in vivo. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1336-1340.7		8
35	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 3783-3794	5.6	55
34	Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia. <i>Acta Diabetologica</i> , <b>2017</b> , 54, 191-199	3.9	7
33	Intestinal bile acid receptors are key regulators of glucose homeostasis. <i>Proceedings of the Nutrition Society</i> , <b>2017</b> , 76, 192-202	2.9	15
32	Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. <i>Gastroenterology</i> , <b>2016</b> , 150, 650-8	13.3	30
31	The novel selective PPAR $\gamma$ modulator (SPPARM) $\gamma$ pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. <i>Atherosclerosis</i> , <b>2016</b> , 249, 200-8	3.1	78
30	Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. <i>International Journal of Obesity</i> , <b>2016</b> , 40, 1260-7	5.5	46
29	Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. <i>Nature Communications</i> , <b>2015</b> , 6, 7629	17.4	202

28	Activation of intestinal peroxisome proliferator-activated receptor- $\alpha$ increases high-density lipoprotein production. <i>European Heart Journal</i> , <b>2013</b> , 34, 2566-74	9.5	36
27	PPAR $\gamma$ activation induces enteroendocrine L cell GLP-1 production. <i>Gastroenterology</i> , <b>2011</b> , 140, 1564-74	13.3	44
26	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. <i>Neurobiology of Disease</i> , <b>2011</b> , 43, 486-94	7.5	111
25	Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. <i>Diabetes</i> , <b>2011</b> , 60, 1861-71	0.9	219
24	Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 1488-95	9.4	55
23	Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 2288-95	9.4	28
22	Intestine-specific regulation of PPAR $\alpha$ gene transcription by liver X receptors. <i>Endocrinology</i> , <b>2008</b> , 149, 5128-35	4.8	27
21	P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2007</b> , 31, 878-86	5.5	20
20	The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, 2731-7	9.4	59
19	Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 340, 1259-63	3.4	135
18	Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. <i>Circulation Research</i> , <b>2005</b> , 97, 682-9	15.7	98
17	Reduced cholesterol absorption upon PPAR $\delta$ activation coincides with decreased intestinal expression of NPC1L1. <i>Journal of Lipid Research</i> , <b>2005</b> , 46, 526-34	6.3	147
16	Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. <i>Journal of Lipid Research</i> , <b>2005</b> , 46, 2717-25	6.3	55
15	Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2004</b> , 1684, 8-17	5	16
14	Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2004</b> , 1683, 69-77	5	5
13	SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2003</b> , 1631, 42-50	5	24
12	Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. <i>Circulation Research</i> , <b>2003</b> , 92, 212-7	15.7	99
11	Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 20625-30	5.4	34

10	Lipid free apolipoprotein E binds to the class B Type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 36092-9	5.4	37
9	Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 293, 1114-23	3.4	27
8	Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2002</b> , 1583, 99-107	5	19
7	PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. <i>Nature Medicine</i> , <b>2001</b> , 7, 53-8	50.5	956
6	Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 763-72	9.4	200
5	Apolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 1074-81	9.4	44
4	Mutation screening of the LDLR gene and ApoB gene in patients with a phenotype of familial hypercholesterolemia and normal values in a functional LDL receptor/apolipoprotein B assay. <i>Clinical Genetics</i> , <b>1998</b> , 54, 79-82	4	8
3	High-density-lipoprotein subfraction 3 interaction with glycosylphosphatidylinositol-anchored proteins. <i>Biochemical Journal</i> , <b>1997</b> , 328 ( Pt 2), 415-23	3.8	19
2	HDL3 binds to glycosylphosphatidylinositol-anchored proteins to activate signalling pathways. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>1997</b> , 1358, 103-12	4.9	8
1	Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes. <i>Atherosclerosis</i> , <b>1996</b> , 120, 209-19	3.1	6